# Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes

> **NCT04861207** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Maria Sklodowska-Curie National Research Institute of Oncology** · enrollment: 40 (estimated)

## Conditions studied

- Acute Myeloid Leukemia Myelodysplastic Syndromes

## Interventions

- **DRUG:** Cladribine

## Key facts

- **NCT ID:** NCT04861207
- **Lead sponsor:** Maria Sklodowska-Curie National Research Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-07
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04861207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04861207, "Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04861207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*